Tag Archives: metabolic

plantsjacques

Optimizing Your LED Spectrum for Leaf Surface Temperature

By Andrew Myers
5 Comments
plantsjacques

Every detail counts at an indoor grow facility. Indoor growers have complete control over nearly every aspect of their crop, ranging from light intensity to air circulation. Among the most important factors to regulate is temperature. While ambient air temperature is critical, growers will also want to measure leaf surface temperature (LST).

To illustrate, let’s say you keep your living room at a cozy 76 degrees. Then, if you place a thermometer under your tongue – your body is (hopefully) not at 76 degrees but is likely between a healthy temperature of 97 to 99 degrees.

A similar story can be told for cannabis plants grown indoors. A grow facility’s ambient air is often different than the plants’ LST. Finding an ideal LST for plant growth can be complex, but modern technology, including spectrally tunable LED grow lights, can simplify monitoring and maintaining this critical aspect.

Why Should Growers Care About LST?

Temperature plays a pivotal role in plant health. Many biochemical reactions contributing to growth and survival only occur within an ideal temperature range. If temperatures dip or spike dramatically, growers may witness inhibited growth, plant stress or irreversible damage to their crops.

The leaf is among the most important plant structures as it’s where most metabolic processes happen. Therefore, finding an optimum LST can improve growth rate and the production of metabolites such as pigments, terpenes, resins and vitamins.

Because many plants rely on their leaves for survival, it makes sense that leaves have their own temperature regulation system. Evaporation through pores in the leaf – known as stomata – can cool the plant through a process called transpiration. Up to 90% of water absorbed is used for transpiration, while 10% is used for growth.

The efficacy of transpiration is determined by the vapor pressure deficit (VPD), which refers to the relative humidity in the ambient air compared to the relative humidity in the leaf. If relative humidity is low, the VPD can be too high, which may cause plants to have withered, leathery leaves and stunted growth. On the other hand, a low VPD correlates to high relative humidity, and can quickly result in disease and mineral deficiencies. Higher humidity often results in a higher LST as transpiration may not be as effective.

When it comes to LST, growers should follow these basic guidelines:

  • Most cannabis plants’ LST should fall between 72 and 86 degrees – generally warmer than the ambient air.
  • LST varies depending on individual cultivar. For example, plants that have evolved in colder climates can generally tolerate cooler temperatures. The same can be said for those evolved in equatorial or temperate climates.
  • CO2 availability also plays a role in LST; CO2 generally raises the target temperature for photosynthesis.

How Does Light Spectrum Affect LST?

We know that CO2 concentration, specific genetic markers and ambient temperature all play an important role in moderating LST. But another important factor at an indoor grow is light spectrum – especially for those using spectrally tunable LEDs. Growers will want to optimize their light spectrum to provide their crop with ideal conditions.

A combination of red and blue wavelengths is shown to have the greatest impact on photosynthesis and, thus, LST. Photons found along the green and yellow wavelengths may not be absorbed as efficiently and instead create heat.

solsticegrowop_feb
Indoor cultivator facilities often use high powered lights that can give off heat

Optimized light spectrums – those with an appropriate balance between red and blue light – create more chemical energy instead of heat, thereby resulting in a lower LST. Using fixtures that are not spectrally tuned for plant growth, on the other hand, can waste energy and ultimately contribute to a higher LST and ambient temperature, negatively affecting plant growth. Consequently, measuring LST doesn’t only indicate ideal growing conditions but also indirectly illustrates the efficiency of your grow lights.

LED fixtures already run at a lower temperature than other lighting technologies, so indoor growers may need to raise the ambient temperature at their grow facilities to maintain ideal LST. Switching to spectrally tuned LEDs may help growers cut down on cooling and dehumidifying costs, while simultaneously improving crop health and productivity.

What’s the Best Way to Measure LST?

There are several tools available for growers to measure LST, ranging from advanced probes to specialty cameras. However, many of these tools provide a reading at a specific point, rather than the whole leaf, leading to some inaccuracies. Temperature can dramatically vary across the leaf, depending if parts are fully exposed to the light or in the shadows.

Investing in a forward-looking infrared camera (FLIR) gives indoor growers a more accurate picture of LST and light efficiency. That being said, growers should not only measure leaves at the top of the plant, but across the middle and bottom of the plant as well. That way, growers receive a complete snapshot of growing conditions and can make changes as needed.

At an indoor grow facility, it’s not enough to only measure ambient room temperature. Of course, this aspect is important, but it will paint an incomplete picture of plant health. Measuring LST gives growers nuanced insights as to how plants respond to their environment and how they can better encourage resilient, healthy growth.

Using spectrally tunable LEDs makes achieving LST easier and more cost-effective. Lights with optimized spectrums for plant growth ensure no energy is wasted – resulting in superior performance and efficiency.

From MedTech to Cannabis: A Q&A with Jennifer Raeder-Devens

By Aaron G. Biros
No Comments

Project Yosemite, a cannabis product innovation and brand development company, announced earlier this month the appointment of Jennifer Raeder-Devens as their new Chief Scientific Officer. Raeder-Devens is a veteran of the MedTech industry, working for companies like Becton Dickinson, Cardinal Health, Medtronic and 3M.

Prior to joining Yosemite, she was the Vice President of Research & Development at Becton, Dickinson, where she oversaw product development and technology strategies to launch infection prevention products including the ChloraPrep first-in-the-US sterile solution patient preoperative topical antiseptic. She was previously the Vice President of R&D, Strategy and Innovation at Cardinal Health. She’s also held roles at Medtronic, 3M Drug Delivery Systems and 3M Skin Health Division and she has a number of patents in drug delivery and medical devices.

Jennifer Raeder-Devens, Chief Scientific Officer at Project Yosemite

In November of 2018, Project Yosemite launched their first product, OLO, which is an infused, controlled-release sublingual strip. Part of Raeder-Devens’ new role at the company is the continued development and expansion of the OLO sublingual strip technology platform. Andrew Mack, CEO and founder of Project Yosemite, says he’s thrilled to have Raeder-Devens on the team. “Jennifer is an extremely accomplished scientist and engineer with extensive experience driving innovation and R&D in the pharmaceutical and medical device industries,” says Mack.

We caught up with Jennifer over the phone to talk about her background in the MedTech space, why she decided to jump ship to join the cannabis industry and what she’s excited to work on now.

Cannabis Industry Journal: Can you tell us about your background, including your work with 3M and Medtronic? 

Jennifer Raeder-Devens: I’m coming directly from Becton Dickinson, a global med tech company, where I supervised the development of drug-device combination products for topical antiseptics. I spent about 10 years there, mostly in topical drug and combination product development. Prior to that, I was at 3M and Medtronic working in drug-device combination products. At 3M, I was supervising a team of technology developers for the 3M Drug Delivery Systems business. I had experience working with designing and manufacturing transdermal, nasal, buccal and inhalation drug delivery mechanisms for pharmaceutical partners.

I worked on implantable drug delivery systems at Medtronic, which included working on the biocompatibility of things like pacemakers and drug infusion pumps and optimizing them to reduce infection and enhance healing after the implantation procedure.

CIJ: What made you consider joining the cannabis industry? 

Jennifer: With my work in topicals, transdermal and inhalation drug delivery, I had an easy understanding of the different routes of administration we see today in the cannabis industry. And so, from the technology standpoint, I thought this was a place I could contribute to immediately. And then what got me really excited about it was thinking about cannabis, and just like any other drug, with oral drug delivery, you’ve got first class metabolism and side effects from the 11-Hydroxy-THC that are undesirable and you’d rather not have delivered through the gut.

OLO sublingual strips have a 10-minute onset time

I got excited when I saw the development of things like sublingual strips that were focusing on alternatives to smoking that would preserve that relatively fast onset and mitigate some of the side effects of edibles.

The other thing I really like about the cannabis industry: Previously I have been very focused on known drugs that are already approved and repurposing them into a new delivery system. What really interests me about the cannabis industry is the active cannabinoids and terpenes are somewhat known and somewhat unknown, so there is this really interesting challenge there of trying to separate the wheat from the chaff in terms of producing therapeutic effects.

It is a really interesting space where the indications of certain molecules are evolving along with the delivery technology. So, it is a really exciting and eye-opening way to take the next step in my career and have this wide-open space in front of me, both in terms of the different cannabinoids, their effects and the delivery systems we can use.

CIJ: How might you be prepared, given your background, for some of the challenges in the cannabis space?

Jennifer: I think the challenges in cannabis delivery are not different from the challenges in pharmaceutical drug delivery. It’s just that we have this additional complexity of the entourage effect. We can be engineering not just the main ingredient of THC, but also all the other cannabinoids and terpenes. So, for example, with my background in infection prevention, we build a product that we know reduces the risk of infection, but we are really challenged to actually prove it reduces the risk of infection. We have a similar situation in the cannabis industry, where we can get the THC, or CBG or CBN where we want it to go, but then we are really challenged to figure out how we can find, what we call in the pharmaceutical industry, a surrogate end point for efficacy, so that we can test that product and really believe that when we put the product on the market, even though we haven’t tested thousands of users or conducted large randomized clinical trials, that the effect will be shown. We are networking and partnering with a good scientific community to build the right product and do some testing at a small scale that really demonstrates the product achieves the effect that we are really looking for.

CIJ: Can you tell us a little about your new role with Project Yosemite?

Jennifer: My job description falls into three buckets: The first part is that we are forming a scientific advisory board and we are working with some of the leading cannabinoid researchers around the country and around the world. These are the people identifying whether or not certain cannabinoids could reduce cancer cell metabolism or whether cannabinoids contribute to weight loss or diabetes control and other things of that nature. We are trying to reach as far upstream as we can to grasp the emerging understanding of the performance of cannabinoids and terpenes in the endocannabinoid system. So, part of my job is to chair that scientific advisory board, get the thought leaders together in the room and have them bring their knowledge and explore with our own knowledge what cannabis can really do.

The OLO sublingual strips

I have worked in topical, transdermal, buccal, nasal, inhalation drug delivery. In the second bucket of my job, we are trying to understand a given indication or experience that our users want to have, what would be the right route for them. We are challenging our sublingual delivery mechanism to see how fast of an onset we can really get. Right now, we are at 10 minutes for drug delivery in sublingual and we are still trying to get an even faster onset time for the sublingual strip.

For other indications, like chronic pain, we may want to think about a sustained release, so sort of aligning the different indications with which different cannabinoids and terpenes will work for it and see which delivery platform will work for what we are trying to accomplish in each indication.  So, we do not plan to remain solely a sublingual strip company, but will build out additional delivery platforms as we develop new indications.

Right now, we are working upstream with the growers and the processors to get cannabis oil and extracts. Some of the growers are working on different genetics in their cultivars to grow plants that have different ratios of different cannabinoids that we know from the emerging research will have an impact on people’s experience. Now we are working with growers to really get ahead of the curve on how to formulate products with various cannabinoids.

We have an R&D team in house that I supervise. We are always working with our production team to make small improvements such as the faster onset and the dissolution rate and things like flavors, which covers a downstream focus as well.